Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses a survey that provided insight into the wide range of advanced practice providers’ chemotherapy prescribing practices throughout the United States and the many discrepancies in privileges (Abstract 1897)...
Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses results from a study that showed patients with lymphoma or chronic lymphocytic leukemia who have taken part in a clinical trial generally are more confident and more involved in their health-care decision-making, reporting having better conversations with their doctors compared to patients who have not participated in a clinical trial (Abstract 3047)...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses data of key importance for advanced practitioners on patients with multiple myeloma who are heavily pretreated and predominantly triple-class refractory, and who relapse after receiving bispecific antibodies (BiAbs)...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engages CD3 on T cells...
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses phase I/II findings from the MajesTEC-1 trial, which seems to confirm that teclistamab monotherapy induces deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma...
Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the largest reported analysis to date of patients with aggressive B-cell lymphoma who developed progressive disease after CAR T-cell therapy...
